Xenikos secures $30m in Series B Financing
Congratulations to our client Xenikos who has raised $30 million from Series B financing.
Dutch company Xenikos are a clinical stage biopharmaceutical company currently developing a novel therapy for treating acute graft-versus-host disease (aGVHD).
The funding will be used to advance the development of Xenikos’ lead compound, T-Guard®. This includes conducting clinical Phase 3 trials for its treatment of aGVHD, a complication of stem cell transplants.